Compare Stocks → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:MTPOTCMKTS:NMUSOTCMKTS:PVOTFOTCMKTS:QBIONASDAQ:VRPX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMTPBiodexa Pharmaceuticals$1.95$0.29▼$5.25$6.18M2.2957,354 shs164,300 shsNMUSNemus Bioscience$10.52$0.05▼$0.74$87.04M-0.04377,395 shs1.00 million shsPVOTFBetterLife Pharma$0.13$0.03▼$0.38$21.70MN/A52,703 shs198,200 shsQBIOQ BioMed$0.00$0.00$0.00▼$0.02$29K1.72538 shsN/AVRPXVirpax Pharmaceuticals$3.10+6.2%$3.70$2.40▼$11.77$3.63M1.3820,195 shs5,246 shsThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMTPBiodexa Pharmaceuticals0.00%0.00%0.00%0.00%0.00%NMUSNemus Bioscience0.00%-94.93%-95.28%-71.11%+4,679.41%PVOTFBetterLife Pharma0.00%0.00%0.00%0.00%0.00%QBIOQ BioMed0.00%0.00%-33.33%-75.00%-98.55%VRPXVirpax Pharmaceuticals-7.12%-26.60%-26.03%-7.72%-57.00%Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMTPBiodexa PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ANMUSNemus BioscienceN/AN/AN/AN/AN/AN/AN/AN/APVOTFBetterLife PharmaN/AN/AN/AN/AN/AN/AN/AN/AQBIOQ BioMedN/AN/AN/AN/AN/AN/AN/AN/AVRPXVirpax PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMTPBiodexa PharmaceuticalsN/AN/AN/AN/ANMUSNemus BioscienceN/AN/AN/AN/APVOTFBetterLife PharmaN/AN/AN/AN/AQBIOQ BioMedN/AN/AN/AN/AVRPXVirpax PharmaceuticalsN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMTPBiodexa Pharmaceuticals$800K0.00N/AN/A$5.67 per share0.00NMUSNemus BioscienceN/AN/AN/AN/A($0.12) per shareN/APVOTFBetterLife PharmaN/AN/AN/AN/A$0.01 per shareN/AQBIOQ BioMed$280K0.10N/AN/A($0.11) per share0.00VRPXVirpax PharmaceuticalsN/AN/AN/AN/A$1.65 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMTPBiodexa Pharmaceuticals-$7.51MN/A0.00N/AN/AN/AN/AN/AN/ANMUSNemus Bioscience-$19.19MN/A0.00N/AN/AN/AN/A-924.42%N/APVOTFBetterLife Pharma-$14.78MN/AN/AN/AN/AN/A-205.15%-147.23%N/AQBIOQ BioMed-$2.05M-$0.03N/A∞N/AN/AN/AN/A5/26/2024 (Estimated)VRPXVirpax Pharmaceuticals-$15.19M-$11.70N/A∞N/AN/A-169.04%-106.39%5/10/2024 (Estimated)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMTPBiodexa PharmaceuticalsN/AN/AN/AN/AN/ANMUSNemus BioscienceN/AN/AN/AN/AN/APVOTFBetterLife PharmaN/AN/AN/AN/AN/AQBIOQ BioMedN/AN/AN/AN/AN/AVRPXVirpax PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMTPBiodexa PharmaceuticalsN/AN/AN/ANMUSNemus BioscienceN/A0.120.12PVOTFBetterLife PharmaN/A3.623.62QBIOQ BioMedN/AN/AN/AVRPXVirpax PharmaceuticalsN/A1.251.25OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMTPBiodexa Pharmaceuticals4.21%NMUSNemus BioscienceN/APVOTFBetterLife PharmaN/AQBIOQ BioMedN/AVRPXVirpax Pharmaceuticals32.23%Insider OwnershipCompanyInsider OwnershipMTPBiodexa Pharmaceuticals0.34%NMUSNemus Bioscience2.70%PVOTFBetterLife Pharma34.77%QBIOQ BioMed28.20%VRPXVirpax Pharmaceuticals6.23%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableMTPBiodexa Pharmaceuticals1821.67 million21.60 millionNot OptionableNMUSNemus BioscienceN/A133.91 millionN/ANot OptionablePVOTFBetterLife PharmaN/A171.41 millionN/ANot OptionableQBIOQ BioMed3145.10 million104.18 millionNot OptionableVRPXVirpax Pharmaceuticals71.17 million1.10 millionNot OptionableQBIO, VRPX, PVOTF, MTP, and NMUS HeadlinesSourceHeadlineVRPX Stock Earnings: Virpax Pharmaceuticals Misses EPS for Q4 2023investorplace.com - April 24 at 3:06 PMVirpax Pharmaceuticals Set for Transformative Year with High Hopes for Non-Addictive Pain Management Solutionsmsn.com - April 2 at 11:02 AMVirpax Pharmaceuticals Reports 2023 Year-End Resultsbusinesswire.com - March 26 at 7:30 AMVirpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Pricefinance.yahoo.com - February 27 at 10:21 AMVirpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Pricebusinesswire.com - February 27 at 7:31 AMVirpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.businesswire.com - February 27 at 7:30 AMVirpax Pharmaceuticals Reports Promising Results in Probudur Pilot Studymsn.com - February 12 at 7:33 AMAnalysts Offer Insights on Healthcare Companies: Virpax Pharmaceuticals (VRPX) and I-MAB (IMAB)markets.businessinsider.com - February 9 at 7:40 AMAnalysts Have Conflicting Sentiments on These Healthcare Companies: Vertex Pharmaceuticals (VRTX) and EyePoint Pharmaceuticals (EYPT)markets.businessinsider.com - February 7 at 3:59 PMVirpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Researchpharmiweb.com - February 7 at 10:56 AMVirpax Pharmaceuticals Inc (VRPX)investing.com - January 23 at 1:47 PMVirpax Pharmaceuticals shareholders okay reverse stock splitmsn.com - December 29 at 7:54 PMTitan Pharmaceuticals to conduct 1-for-20 reverse stock splitmsn.com - December 28 at 6:06 PMVRPX Virpax Pharmaceuticals, Inc.seekingalpha.com - November 22 at 3:08 PMPromising Pipeline Developments and Market Opportunities Drive Buy Rating for Virpax Pharmaceuticalsmarkets.businessinsider.com - November 18 at 12:51 AMVirpax Pharmaceuticals gets non-compliance notice from Nasdaqmsn.com - November 17 at 9:20 AMVirpax Pharmaceuticals CEO and Chairman resigns on ongoing litigationmsn.com - November 17 at 9:20 AMVirpax Pharmaceuticals Announces Leadership Transitionfinance.yahoo.com - November 17 at 9:20 AMVirpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filingfinance.yahoo.com - November 17 at 9:20 AMVirpax Pharmaceuticals GAAP EPS of -$0.51msn.com - November 15 at 7:29 PMVirpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Reviewfinance.yahoo.com - October 31 at 10:01 AMAnalysts Are Bullish on These Healthcare Stocks: Virpax Pharmaceuticals (VRPX), Kura Oncology (KURA)markets.businessinsider.com - September 28 at 4:00 PMVirpax Pharmaceuticals Announces Results of Probudur™ Dose Escalation Studiesfinance.yahoo.com - September 27 at 1:53 PMVirpax Pharmaceuticals to Present at the LD Micro Main Event XVIfinance.yahoo.com - September 26 at 2:19 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBiodexa PharmaceuticalsNASDAQ:MTPBiodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.Nemus BioscienceOTCMKTS:NMUSNemus Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics. The company's product candidates in preclinical stage include NB1111 for the treatment of glaucoma; NB1222 used for treating chemotherapy induced nausea and vomiting; and NB3111 for the treatment of methicillin-resistant staphylococcus aureus. Its products under research comprise NB2111 for use in treating chemotherapy induced peripheral neuropathy; and NB2222 for the treatment of uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy. Nemus Bioscience, Inc. has a license agreement with the University of Mississippi to research, develop, and commercialize products for the treatment of infectious diseases. The company was founded in 2012 and is headquartered in Costa Mesa, California.BetterLife PharmaOTCMKTS:PVOTFBetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. It also offers drug delivery platform technologies. Its product lines include capsules, tablets, and softgels; bulk powder; stick packs; beverages; oral solutions; lotions, creams, and gels; pet food additives; gum, mints, and candies; and sexual health products. It distributes its product under the Pivot Naturals brand. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada.Q BioMedOTCMKTS:QBIOQ BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.Virpax PharmaceuticalsNASDAQ:VRPXVirpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.